The road less traveled: activating an oncogenic kinase

Madhuri Paul; David A Fruman

doi:10.1016/j.tips.2023.07.005

The road less traveled: activating an oncogenic kinase

Trends Pharmacol Sci. 2023 Oct;44(10):640-642. doi: 10.1016/j.tips.2023.07.005. Epub 2023 Aug 7.

Authors

Madhuri Paul¹, David A Fruman²

Affiliations

¹ Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA.
² Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA. Electronic address: dfruman@uci.edu.

PMID: 37553270
DOI: 10.1016/j.tips.2023.07.005

Abstract

Elevated phosphoinositide 3-kinase (PI3K) activity in human tumors has prompted widespread efforts to develop chemical PI3K inhibitors for oncology indications. In an innovative new study, Gong et al. report the discovery of a highly selective activator of the PI3Kα isoform, with promising activity in assays of nerve regrowth and cardioprotection from ischemia-reperfusion injury (IRI).

Keywords: PI3K; kinase; oncogene; targeted therapy.

MeSH terms

Humans
Phosphatidylinositol 3-Kinases*
Phosphoinositide-3 Kinase Inhibitors
Protein Isoforms
Reperfusion Injury*

Substances

Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Protein Isoforms